KANE BIOTECH INC (KNE.CA) Stock Price, Forecast & Analysis
Canada - TSX-V:KNE - CA4838092084 - Common Stock
KNE.CA Key Statistics, Chart & Performance
The current stock price of KNE.CA is 0.04 CAD. In the past year, price decreased by -61.9%.
KNE.CA Latest News, Press Relases and Analysis
KNE.CA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| EPRX.CA | EUPRAXIA PHARMACEUTICALS INC | N/A | 470.58M | ||
| EDT.CA | SPECTRAL MEDICAL INC | N/A | 406.00M | ||
| HBP.CA | HELIX BIOPHARMA CORP | N/A | 179.49M | ||
| MDNA.CA | MEDICENNA THERAPEUTICS CORP | N/A | 118.44M | ||
| COV.CA | COVALON TECHNOLOGIES LTD | 24.88 | 54.57M | ||
| MBX.CA | MICROBIX BIOSYSTEMS INC | N/A | 34.18M | ||
| RVX.CA | RESVERLOGIX CORP | N/A | 28.67M | ||
| BCT.CA | BRIACELL THERAPEUTICS CORP | N/A | 24.31M | ||
| HEM.CA | HEMOSTEMIX INC | N/A | 16.56M | ||
| MPH.CA | MEDICURE INC | N/A | 13.05M | ||
| CSCI.CA | COSCIENS BIOPHARMA INC | N/A | 10.72M | ||
| QPT.CA | QUEST PHARMATECH INC | N/A | 6.77M |
Related stock screener links
About KNE.CA
Company Profile
Kane Biotech, Inc. is a biotechnology company, which engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms. The company is headquartered in Winnipeg, Manitoba. The company went IPO on 2003-05-07. The Company’s segments include Animal health, and Human health. The company has a portfolio of technologies, intellectual property (patents, patents pending and trademarks) and products developed by the Company’s own biofilm research and acquired from research institutions. DispersinB, coactiv+TM, coactiv+, DermaKBTM, DermaKB BiofilmTM and revyveTM are trademarks of Kane Biotech. Its patented coactiv+ technology is specifically formulated to destabilize biofilm and create an environment for fast wound healing. The firm's other biofilm disruption technology is DispersinB. DispersinB is a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine (PNAG). DispersinB cleaves PNAG, inhibiting bacterial adhesion and disperses the biofilm.
Company Info
KANE BIOTECH INC
290-100 Innovation Drive
Winnipeg MANITOBA R3T 2N2 CA
CEO: Marc Edwards
Employees: 0
Phone: 12044531301
KANE BIOTECH INC / KNE.CA FAQ
What does KNE do?
Kane Biotech, Inc. is a biotechnology company, which engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms. The company is headquartered in Winnipeg, Manitoba. The company went IPO on 2003-05-07. The Company’s segments include Animal health, and Human health. The company has a portfolio of technologies, intellectual property (patents, patents pending and trademarks) and products developed by the Company’s own biofilm research and acquired from research institutions. DispersinB, coactiv+TM, coactiv+, DermaKBTM, DermaKB BiofilmTM and revyveTM are trademarks of Kane Biotech. Its patented coactiv+ technology is specifically formulated to destabilize biofilm and create an environment for fast wound healing. The firm's other biofilm disruption technology is DispersinB. DispersinB is a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine (PNAG). DispersinB cleaves PNAG, inhibiting bacterial adhesion and disperses the biofilm.
What is the current price of KNE stock?
The current stock price of KNE.CA is 0.04 CAD.
What is the dividend status of KANE BIOTECH INC?
KNE.CA does not pay a dividend.
How is the ChartMill rating for KANE BIOTECH INC?
KNE.CA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the market cap for KANE BIOTECH INC?
KANE BIOTECH INC (KNE.CA) has a market capitalization of 6.63M CAD. This makes KNE.CA a Nano Cap stock.
KNE.CA Technical Analysis
KNE.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to KNE.CA. Both the profitability and financial health of KNE.CA have multiple concerns.
KNE.CA Financial Highlights
Over the last trailing twelve months KNE.CA reported a non-GAAP Earnings per Share(EPS) of -0.01. The EPS decreased by -815.79% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -87.22% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |